POMT1: A Promising Drug Target and Biomarker for Protein O-mannosyl-Transferase 1

Target Name: POMT1

NCBI ID: G10585

POMT1

POMT1: A Promising Drug Target and Biomarker for Protein O-mannosyl-Transferase 1

Introduction

Protein O-mannosyl-transferase 1 (POMT1) is a critical enzyme involved in the transfer of O-mannosyl groups to target proteins, which is a key step in various cellular processes. POMT1 functions as a negative regulator, promoting protein degradation and limiting their levels in the cell. The deregulation of POMT1 has been implicated in various diseases, including neurodegenerative disorders, cancer, and inflammation. Therefore, targeting POMT1 has emerged as a promising strategy for developing new therapeutic approaches. In this article, we will discuss POMT1 as a drug target and biomarker, highlighting its current status, the scientific evidence supporting its potential as a drug target, and the ongoing research in this field.

Current Status of POMT1 Research

POMT1 has been extensively studied over the years, and recent studies have shed new light on its functions and potential as a drug target. The majority of the research has focused on the characterization of POMT1 as a protein and its role in various cellular processes.

1. Functional characterization of POMT1

POMT1 is a 21-kDa protein that is expressed in various cell types, including neurons, glia, and endothelial cells. It is highly conserved across species, and its primary structure is similar to that of other members of the POMT family. POMT1 has a distinct N-terminus that contains a catalytic core and a C-terminus that is involved in its interactions with other proteins.

Recent studies have provided new insights into the functional characterization of POMT1. For instance, researchers have shown that POMT1 plays a critical role in the regulation of protein stability and degradation. POMT1 has been shown to interact with various protein partners, including its own substrate, is the Social Acceptance Receptor (SOR), and the protein involved in the detoxification of foreign substances, called X-ray.

1. Potential as a drug target

The potential of POMT1 as a drug target is based on its unique functions and the involvement of various cellular processes. POMT1 has been shown to play a critical role in the regulation of protein stability and degradation, which could make it an attractive target for small molecules that can modulate its activity.

POMT1 has been shown to be a validated drug target by various methods, including cell-based assays and in vitro assays. For instance, researchers have shown that inhibition of POMT1 can lead to the accumulation of POMT1-deficient protein in the cell, which can cause a variety of cellular processes to be altered.

1. Biomarker potential

POMT1 has also been shown to be a potential biomarker for various diseases, including neurodegenerative disorders, cancer, and inflammation. The levels of POMT1 have been shown to be altered in the brains of individuals with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Furthermore, POMT1 has been shown to be involved in the regulation of cancer cell growth and metastasis.

Conclusion

POMT1 is a well-established enzyme that has been involved in various cellular processes. Its functions have been extensively characterized, and recent studies have shown that it has the potential to be a drug target for small molecules. Furthermore, POMT1 has also been shown to be a potential biomarker for various diseases. Given its unique functions and the involvement of various cellular processes, POMT1 is an attractive target for small molecules that can modulate its activity. As research in this field continues to advance, we can expect to see new therapeutic approaches emerge that target POMT1.

Protein Name: Protein O-mannosyltransferase 1

Functions: Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:12369018, PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

The "POMT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POMT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets